GPCR somatostatin receptor extracellular loop 2 is a key ectodomain for making subtype-selective antibodies with agonist-like activities in the pancreatic neuroendocrine tumor BON cell line

Pancreas

Volumn 39, Issue 8, 2010, Pages 1155-1166

  Leu, Frank P ^a   Nandi, Minesh ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

extracellular loop 2; G proteinYcoupled receptors; GEP NET; neuroendocrine tumor; somatostatin receptors; subtype selective SSTR antibodies

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 2 ANTIBODY; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 3 ANTIBODY; SOMATOSTATIN RECEPTOR 5; SOMATOSTATIN RECEPTOR 5 ANTIBODY; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; DRUG MECHANISM; HUMAN; HUMAN CELL; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN DOMAIN; SEROTONIN RELEASE;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; APOPTOSIS; BINDING SITES; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CYCLIC AMP; HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, SOMATOSTATIN; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEROTONIN;

EID: 78049287614     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181de8c05     Document Type: Article

References (51)

1. Greenwood MT, Hukovic N, Kumar U, et al. Ligand binding pocket of the human somatostatin receptor 5: mutational analysis of the extracellular domains. Mol Pharmacol. 1997;52(5):807-814.
2. Trabanino RJ, Hall SE, Vaidehi N, et al. First principles predictions of the structure and function of G-protein-coupled receptors: validation for bovine rhodopsin. Biophys J. 2004;86(4):1904-1921.
3. Cherezov V, Rosenbaum DM, Hanson MA, et al. High-resolution crystal structure of an engineered human 2-adrenergic G protein coupled receptor. Science. 2007;318(5854):1258-1265.
4. Rosenbaum DM, Cherezov V, Hanson MA, et al. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science. 2007;318(5854):1266-1273.
5. Rasmussen SGF, Choi H-J, Rosenbaum DM, et al. Crystal structure of the human beta2 adrenergic G-proteinYcoupled receptor. Nature. 2007;450(7168):383- 387.
6. Reisine T, Kong H, Raynor K, et al. Splice variant of the somatostatin receptor 2 subtype, somatostatin receptor 2B, couples to adenylyl cyclase. Mol Pharmacol. 1993;44(5):1016-1020.
7. Pradayrol L, Jornvall H, Mutt V, Ribet A. N-terminally extended somatostatin: the primary structure of somatostatin-28. FEBS Lett. 1980;109(1):55-58.
8. Benali N, Cordelier P, Calise D, et al. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci U S A. 2000;97(16):9180-9185.
9. Buscail L, Esteve J, Saint-Laurent N, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci U S A. 1995;92(5):1580-1584.
10. Vernejoul F, Faure P, Benali N, et al. Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res. 2002;62(21):6124-6131.
11. Lahlou H, Guillermet J, Hortala M, et al. Molecular signaling of somatostatin receptors. Ann N Y Acad Sci. 2004;1014:121-131.
12. Benali N, Ferjoux G, Puente E, et al. Somatostatin receptors. Digestion. 2000;62(suppl 1):27-32.
13. Kulaksiz H, Eissele R, Rossler D, et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut. 2002;50(1):52-60.
14. Gu YZ, Schonbrunn A. Coupling specificity between somatostatin receptor sst2A and G proteins: isolation of the receptor-G protein complex with a receptor antibody. Mol Endocrinol. 1997;11(5): 527-537.
15. Leu FP, Nandi M, Niu C. The effect of transforming growth factor beta on human neuroendocrine tumor BON cell proliferation and differentiation is mediated through somatostatin signaling. Mol Cancer Res. 2008;6(6):1029-1042.
16. Bachman KE, Park BH. Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoter. Curr Opin Oncol. 2005;17(1):49-54.
17. Bousquet C, Guillermet J, Vernejoul F, et al. Somatostatin receptors and regulation of cell proliferation. Dig Liver Dis. 2004;36(suppl 1):S2-S7.
18. Jeffrey Conn P, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov. 2009;8(1):41-54.
19. Evers BM, Townsend CM, Jr., Upp JR, et al. Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology. 1991;101(2): 303-311.
20. Kaupmann K, Bruns C, Raulf F, et al. Two amino acids, located in transmembrane domains VI and VII, determine the selectivity of the peptide agonist SMS 201-995 for the SSTR2 somatostatin receptor. EMBO J. 1995;14(4):727-735.
21. Nehring RB, Meyerhof W, Richter D. Aspartic acid residue 124 in the third transmembrane domain of the somatostatin receptor subtype 3 is essential for somatostatin-14 binding. DNA Cell Biol. 1995;14(11): 939-944.
22. Strnad J, Hadcock JR. Identification of a critical aspartate residue in transmembrane domain three necessary for the binding of somatostatin to the somatostatin receptor SSTR2. Biochem Biophys Res Commun. 1995;216(3):913-921.
23. Sprang SR. Structural biology: a receptor unlocked. Nature. 2007; 450(7168):355-356.
24. Cescato R, Schulz S, Waser B, et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med. 2006;47(3):502-511.
25. Korner M, Eltschinger V, Waser B, et al. Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography. Am J Surg Pathol. 2005;29(12):1642-1651.
26. Plonowski A, Schally AV, Nagy A, et al. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Cancer Res . 1999;59(8): 1947-1953.
27. Guillermet J, Saint-Laurent N, Rochaix P, et al. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci U S A. 2003;100(1): 155-160.
28. Schaer JC, Waser B, Mengod G, et al. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer. 1997;70(5): 530-537.
29. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20(3):157-198.
30. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: a G proteinYcoupled receptor. Science. 2000;289(5480): 739-745.
31. Gobeil F, Fortier A, Zhu T, et al. G-proteinYcoupled receptors signalling at the cell nucleus: an emerging paradigm. Can J Physiol Pharmacol. 2006;84(3-4):287-297.
32. Kobilka BK, Deupi X. Conformational complexity of G-proteinYcoupled receptors. Trends Pharmacol Sci. 2007;28(8):397-406.
33. Kobilka BK. G protein coupled receptor structure and activation. Biochim Biophys Acta. 2007;1768(4):794-807.
34. Reardon DB, Dent P, Wood SL, et al. Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected ras-transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness. Mol Endocrinol Mol Endocrinol. 1997;11(8):1062.
35. Garcia de la Torre N, Wass JA, Turner HE. Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxford). 2002;57(4): 425-441.
36. Oberg K. Neuroendocrine gastrointestinal tumorsYa condensed overview of diagnosis and treatment. Ann Oncol. 1999;10(suppl 2): S3-S8.
37. Oberg K. Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol. 2002;14(1): 38-45.
38. Mulkeen A, Cha C. Gastric carcinoid. Curr Opin Oncol. 2005;17(1): 1-6.
39. Desjarlais JR, Lazar GA, Zhukovsky EA, et al. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today. 2007;12(21-22):898-910.
40. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6(5):343-357.
41. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006;6: 859-866.
42. De Lorenzo C, Cozzolino R, Carpentieri A, et al. Biological properties of a human compact anti-ErbB2 antibody. Carcinogenesis. 2005; 26(11):1890-1895.
43. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23(9):1147-1157.
44. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995;1(11):1311-1318.
45. Dutta PR, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett. 2007;254:165-177.
46. Rohrer SP, Birzin ET, Mosley RT, et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science. 1998;282(5389):737-740.
47. Rocheville M, Lange DC, Kumar U, et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science. 2000;288(5463):154-157.
48. Rocheville M, Lange DC, Kumar U, et al. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem. 2000;275(11):7862-7869.
49. Pfeiffer M, Koch T, Schroder H, et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem. 2001;276(17): 14027-14036.
50. Patel RC, Lange DC, Patel YC. Photobleaching fluorescence resonance energy transfer reveals ligand-induced oligomer formation of human somatostatin receptor subtypes. Methods. 2002;27(4):340-348.
51. Patel RC, Kumar U, Lamb DC, et al. Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc Natl Acad Sci U S A. 2002;99(5):3294-3299.